Istradefylline is a selective adenosine A2A receptor antagonist approved as an adjunctive treatment for adults with Parkinson's disease, specifically to reduce the duration of "off" episodes in patients… Read more
























Istradefylline is a selective adenosine A2A receptor antagonist approved as an adjunctive treatment for adults with Parkinson's disease, specifically to reduce the duration of "off" episodes in patients taking levodopa/carbidopa. Ensuring the quality, safety, and efficacy of this therapeutic agent requires rigorous analytical testing throughout the development and manufacturing process. Our catalogue provides high-quality reference standards of Istradefylline, along with its related compounds, including pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites. These compounds are essential for accurate impurity profiling, method validation, and routine quality control. Furthermore, stable isotope labelled compounds are available to serve as internal standards for precise quantitative analysis, enabling laboratories to identify and monitor structurally related analogs and potential degradation products formed through pathways such as hydrolysis, oxidation, and photolysis.